Jazeta Novum (Sitagliptin Phosphate Monohydrate)

Jazeta Novum (sitagliptin) is used in the management of type 2 diabetes mellitus, a chronic disorder of glucose metabolism.

• Type 2 diabetes mellitus: improves glycemic control when added to diet and exercise.
• Inadequate control on metformin alone: provides additional HbA1c reduction as part of combination therapy.
• Combination with sulfonylureas: enhances overall glucose lowering while allowing dose adjustments of co‑medications.

• Sitagliptin phosphate monohydrate selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the degradation of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, leading to reduced post‑prandial and fasting blood glucose concentrations.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nose and throat.
• Headache: transient cranial pain.
• Upper respiratory tract infection: symptoms such as cough and congestion.
• Nausea: occasional stomach upset.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain and elevated enzymes.
• Severe allergic reactions: including rash, angioedema, or anaphylaxis.
• Joint pain (arthralgia): persistent musculoskeletal discomfort.
• Bullous pemphigoid: rare blistering skin disorder.

When prescribing Jazeta Novum, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: dose may need adjustment in patients with reduced kidney function.
• Hepatic impairment: use with caution in moderate liver disease.
• Hypoglycemia risk: monitor blood glucose when combined with insulin or sulfonylureas.
• History of pancreatitis: avoid or use only if benefits outweigh risks.
• Cardiovascular disease: assess patient’s cardiac status as sitagliptin has a neutral CV profile.
• Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Insulin or sulfonylureas: increased risk of hypoglycemia.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin plasma concentrations.
• Rifampin: may reduce sitagliptin exposure, decreasing effectiveness.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Diuretics: watch for changes in blood pressure and electrolytes.
• Warfarin: periodic INR testing recommended.